Helen T. Chifotides, PhD | Authors


New Therapies in Development for Myelofibrosis

October 15, 2020

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.